Pradefovir: A prodrug that targets adefovir to the liver for the treatment of hepatitis B

Journal of Medicinal Chemistry

Volumn 51, Issue 3, 2008, Pages 666-676

  Reddy, K Raja ^a   Matelich, Michael C ^a   Ugarkar, Bheemarao G ^a   Gómez Galeno, Jorge E ^a   DaRe, Jay ^a   Ollis, Kristin ^a   Sun, Zhili ^a   Craigo, William ^a   Colby, Timothy J ^a   Fujitaki, James M ^a   Boyer, Serge H ^a   Van Poelje, Paul D ^a   Erion, Mark D ^a  

^a Metabasis Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 PROPANYL DERIVATIVE; 9 [2 [4 (3 CHLOROPHENYL) 2 OXO 1,3,2 DIOXAPHOSPHORINAN 2 YL]METHOXYMETHYL]ADENINE; ADEFOVIR DIPHOSPHATE; ADEFOVIR DIPIVOXIL; DRUG METABOLITE; MESYLIC ACID; PRADEFOVIR; PRODRUG; PROPANE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL ACTIVATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HEPATITIS B; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY; LIVER; LIVER MICROSOME; MALE; NONHUMAN; RAT; STEREOCHEMISTRY; TISSUE DISTRIBUTION; TISSUE SPECIFICITY;

ADENINE; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; HEPATOCYTES; LIVER; MALE; MICROSOMES, LIVER; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 39149114424     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7012216     Document Type: Article

References (41)

1. Lavanchy, D. J. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004, 11 (2), 97-107.
2. Wong, D. K. H.; Cheung, A. M.; O'Rourke, K.; Naylor, C. D.; Detsky, A. S.; Heathcote, J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 1993, 119, 312-323.
3. (a) Lai, C. L.; Chien, R. N.; Leung, N. W. Y.; Chiang, T. T.; Guan, R.; Tai, D. I.; Ng, K. Y.; Wu, P. C.; Dent, J. C.; Barber, J.; Stephenson, S. L.; Gray, D. F. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998, 339, 61-68.
4. (b) Lok, A. S.; Hussain, M.; Cursano, C.; Margotti, M.; Gramenzi, A.; Grazi, G. L.; Jovine, E.; Benardi, M.; Andreone, P. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000, 32 (5), 1145-1153.
5. (a) Marcellin, P.; Chang, T. T.; Lim, S. G.; Tong, M. J.; Sievert, W.; Shiffman, M. L.; Jeffers, L.; Goodman, Z.; Wulfsohn, M. S.; Xiong, S.; Fry, J.; Brosgart, C. L. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 2003, 348 (9), 808-816.
6. (b) Hadziyannis, S.; Tassopoulos, N.; Chang, T.; Heathcote, E. J.; Kitis, G.; Rizzetto, M.; et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy. Hepatology 2005, 42 (Suppl.), 754A (Abstract).
7. (a) Lai, C. L.; Shouval, D.; Lok, A. S.; Chang, T. T.; Cheinquer, H.; Goodman, Z.; DeHertogh, D.; Wilber, R.; Zink, R. C.; Cross, A.; Colonno, R.; Fernandes, L. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006, 354 (10), 1011-1020.
8. (b) Kim, J. W.; Park, S. H.; Louie, S. G. Telbivudine: a novel nucleoside analogue for chronic hepatitis B. Ann. Pharmacother. 2006, 40 (3), 472-478.
9. (a) Maynard, M.; Parvaz, P.; Durantel, S.; Chevallier, M.; Chevallier, P.; Lot, M.; Trepo, C.; Zoulim, F. Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. J. Hepatol. 2005, 42 (2), 279-281.
10. (b) Westland, C. E.; Yang, H.; Delaney, W. E.; Wulfsohn, M.; Lama, N.; Gibbs, C. S.; Miller, M. D.; Fry, J.; Brosgart, C. L.; Schiff, E. R.; Xiong, S. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J. Viral. Hepat. 2005, 12 (1), 67-73.
11. Tanji, N.; Tanji, K.; Kambham, N.; Markowitz, G. S.; Bell, A.; D'agati, V. D. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum. Pathol. 2001, 32 (7), 734-740.
12. (a) Erion, M. D.; Reddy, K. R.; Boyer, S. H.; Matelich, M. C.; Gomez-Galeno, J.; Lemus, R. H.; Ugarkar, B. G.; Colby, T. J.; Schanzer, J.; van Poelje, P. D. Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J. Am. Chem. Soc. 2004, 126, 5154-5163.
13. (b) Erion, M. D.; van Poelje, P. D.; MacKenna, D. A.; Colby, T. J.; Montag, A.; Fujitaki, J. M.; Linemeyer, D. L.; Bullough, D. A. Liver-targeted drug delivery using HepDirect prodrugs. J. Pharmacol. Exp. Ther. 2005, 312 (2), 554-560.
14. Meunier, B.; de Visser, S. P.; Ahaik, S. Mechanism of oxidation reactions catalyzed by cytochrome P450 enzymes. Chem. Rev. 2004, 104, 3947-3980.
15. For recent prodrug reviews, see the following, (a) Krise, J. P.; Stella, V. J. Adv. Drug Delivery Rev. 1996, 19, 287-310.
16. (b) Freeman, S.; Ross, K. C. In Progress in Medicinal Chemistry; Ellis, G. P., Luscombe, D. K., Eds.; Elsevier Science: Amsterdam, 1997; Vol. 34, pp 111-147.
17. (c) Schultz, C. Prodrugs of biologically active phosphate esters. Bioorg. Med. Chem. 2003, 11 (6), 885-898.
18. (a) Holy, A.; Rosenberg, I. Synthesis of 9-[2-(phosphonylmethoxy)ethyl] adenine and related compounds. Collect. Czech. Chem. Commun. 1987, 52, 2801-2809.
19. (b) Holy, A. Isopolar Phosphorus-Modified Nucleotide Analogues. In Advances in Antiviral Drug Design, 1st ed.; De Clercq, E., Ed.; JAI Press, Inc.: Greenwich, CT, 1994; pp 179-232.
20. (a) Turner, J. A. A general approach to the synthesis of 1,6-, 1,7-, and 1,8-naphthyridines. J. Org. Chem. 1990, 55, 4744-1750.
21. (b) Coppi, L.; Ricci, A.; Taddei, M. Lewis acid-mediated condensation of alkenols and aldehydes. A selective synthesis of tetrahydropyrans and oxepanes. J. Org. Chem. 1988, 53, 911-913.
22. 5 complexes and their intramolecular and oxygen-transfer reaction. Tetrahedron 1981, 37, 1871-1873.
23. (d) McGarvey, G. J.; Bajwa, J. S. Studies on the stereoselective hydroboration of vinyl ethers. Tetrahedron Lett. 1985, 26, 6297.
24. (a) Starrett, J. E., Jr.; Tortolani, D. R.; Russell, J.; Hitchcock, M. J. M.; Whiterock, V.; Martin, J. C.; Mansuri, M. M. Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (ADV). J. Med. Chem. 1994, 37, 1857-1864.
25. (b) Machleidt, H.; Cohnen, E.; Tschesche, R. Syntheses of DL-mevalonic acid 3,5-cyclophosphate and DL-mevalonic acid 5-phosphate. Ann. 1962, 655, 70-80.
26. (a) Mosbo, J.; Verkade, J. G. A. Dipole moment, nuclear magnetic resonance, and infrared studies of phosphorus configurations and equilibriums in 2-R-2-oxo-1,3,2-dioxaphosphorinanes. J. Org. Chem. 1977, 42, 1549-1555.
27. (b) Cooper, D. B.; Harrison, J. M.; Inch, T. D.; Lewis, G. J. Use of carbohydrate derivatives for studies of phosphorus stereochemistry. Part II. Synthesis and configurational assignments of 1,3,2-oxathiaphosphorinan-2-ones and 1,3,2-dioxaphosphorinan-2-thiones. J. Chem. Soc., Perkin Trans. 1 1974, 1049-1052.
28. Reddy, K. R.; Boyer, S. H.; Erion, M. D. Stereoselective synthesis of nucleoside monophosphate HepDirect prodrugs. Tetrahedron Lett. 2005, 46, 4321-1324.
29. (a) Harada, T.; Kurokawa, H.; Oku, A. Resolution of 1,3-alkanediols via chiral spiroketals derived from 2-menthone. Tetrahedron Lett. 1987, 28, 4843-1846.
30. f values of the diastereomeric menthone ketals on thin layer chromatography (TLC).
31. Reddy, K. R.; Erion, M. D.; Matelich, M. C.; Kopcho, J. J. U.S. Patent 7,214,668, 2007.
32. Boyer, S. H.; Sun, Z.; Jiang, H.; Esterbrook, J.; Gómez-Galeno, J. E.; Craigo, W.; Reddy, K. R.; Ugarkar, B. G.; MacKenna, D. A.; Erion, M. D. Synthesis and characterization of a novel cyclic 1-aryl-1,3-propanyl prodrug of cytarabine monophosphate (MB07133) for the treatment of hepatocellular carcinoma. J. Med. Chem. 2006, 49, 7711-7720.
33. (a) Erion, M. D.; Bullough, D. A.; Lin, C.-C.; Hong, Z. HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver. Curr. Opin. Invest. Drugs 2006, 7, 109-117.
34. (b) Lee, K. S.; Lim, S. G.; Chuang, W. L.; Hwang, S. G.; Cho, M.; Lai, M. Y.; Chao, Y. C.; Chang, T-T.; Han, K. H.; Lee, C. M.; Um, S. H.; Yeon, J. E.; Yang, S. S.; Teo, E. K.; Peng, C. Y.; Lin, H. H.; Yang, S. S.; Huo, T. I.; Nguyen, T.; Chen, T. Y.; Hu, K. Q.; Xu, Y.; Sullivan-Bólyai, J. Z. Safety, tolerability, and antiviral activity of pradefovir mesylate in patients with chronic hepatitis B virus infection: 48-week analysis of a phase 2 study. J. Hepatol. 2006, 44 (S2), S274.
35. (c) Lin, C.-C.; Xu, C.; Teng, A.; Yeh, L.-T.; Peterson, J. Pharmacokinetics of pradefovir and ADV in healthy volunteers after oral dosing of pradefovir. J. Clin. Pharmacol 2005, 45 (11), 1250-1258.
36. (d) Lin, C.-C.; Chao, Y.-C.; Lai, M.-Y.; Chang, T.-T.; Chuang, W.-L.; Yang, S.-S.; Braeckman, R.; Chen, D.-S. Safety, tolerance, pharmacokinetics and pharmacodynamics of remofovir, a liver-targeting prodrug of ADV in HBV patients following daily dosing for 28 days. Hepatology 2004, 40 (S1), A1141-A1142.
37. (e) Lin, C. C.; Yeh, L. T.; Vitarella, D.; Hong, Z.; Erion, M. D. Remofovir mesylate: a prodrug of ADV with improved liver-targeting and safety in rats and monkeys. Antiviral Chem. Chemother. 2004, 15 (6), 307-317.
38. (a) Russell, J. W.; Marrero, D.; Whiterock, V. J.; Klunk, L. J.; Starret, J. E. Determination of 9-[(2-phosphonylmethoxy)ethyl]adenine in rat urine by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. 1991, 572, 321-326.
39. (b) Shaw, J. P.; Louie, M. S.; Krishnamurthy, V. V.; Arimilli, M. N.; Jones, R. J.; Bidgood, A. M.; Lee, W. A.; Cundy, K. C. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Drug Metab. Dispos. 1997, 25, 362-366.
40. Berry, M. N.; Friend, D. S. J. Cell Biol. 1969, 43, 506-520.
41. Groen, A. K.; et al. Eur. J. Biochem 1982, 122, 87-93.